Routinely measuring neurofilaments in the blood and spinal fluid of people with amyotrophic lateral sclerosis (ALS) can help identify patients with early symptoms, concludes a recent study. Researchers led by Dr. Emily Feneberg of England’s University of Oxford presented the study, “Multicenter evaluation of neurofilaments in early symptom onset amyotrophic…

The company Verge Genomics, which uses genomic data for neuroscience therapeutics, announced that it will join specialized departments at four top universities to boost research in amyotrophic lateral sclerosis (ALS). The innovative industry-academic collaboration will combine machine learning with genomic, genetic, biological, and phenotypical data to accelerate the translation…

Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that it will receive $30 million in financing to develop treatments for axonal degeneration. Disarm was founded in 2016 as a…

This 2014 Roundabout U video is all about Todd Walker from Murray, Kentucky. Todd shares his ALS story, which began when he was suddenly unable to exercise like usual. At first, doctors thought Todd was suffering from depression as he had just lost his father but as his symptoms began…

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Revalesio’s investigational drug RNS60 to treat amyotrophic lateral sclerosis (ALS). The status gives incentives for companies to develop new therapies targeting rare and serious diseases, providing marketing exclusivity for…

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, the drug developer, announced in a press release. Orphan drug status aims to encourage therapies for rare and serious diseases through incentives such as seven years of market…

Neuroscientist and professor Niels Birbaumer, a senior research fellow at Switzerland’s Wyss Center in Geneva, has written a new book investigating the brain’s seemingly limitless capacity  to reshape itself and overcome disease. Birbaumer has conducted research with amyotrophic lateral sclerosis (ALS) patients who, because of their progressive motor neuron disease, have…

The investigational gene therapy VM202, developed by VM BioPharma and intended for the treatment of amyotrophic lateral sclerosis (ALS), has been shown to be safe and well-tolerated in a small Phase 1/2 clinical trial, according to data published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. While the study,…

In this video from CBS Sunday Morning, follow the journey of award-winning filmmaker Simon Fitzmaurice as he completes his pet project, a film called My Name is Emily, despite being diagnosed with amyotrophic lateral sclerosis (ALS) eight years ago. MORE: Explaining the progression…